vimarsana.com
Home
Live Updates
TriSalus Reports Q4 and Full Year 2023 Financial Results and Business Update : vimarsana.com
TriSalus Reports Q4 and Full Year 2023 Financial Results and Business Update
Reported revenues of $5.7 million in 4Q23, up 77% over prior year
Full year revenues of $18.5 million, up 49% over prior year
Gross Margin of 90% in 4Q23 and 86% for full year
CMS...
Related Keywords
Texas ,
United States ,
Mary Szela ,
Intrahepatic Cholangiocarcinoma ,
Trisalus Life Sciences ,
Centers For Medicare Medicaid Services ,
Linkedin ,
Academic Oncology Centers ,
University Of Texas Md Anderson Cancer Center ,
Nasdaq ,
Company Annual Report On Form ,
Twitter ,
Technology Healthcare Common Procedure Coding System ,
Exchange Commission ,
Trisalus Life Sciences Inc ,
Society For Immunotherapy ,
Current Medical Research ,
Chief Executive Officer ,
Trinav Infusion System ,
Medicaid Services ,
Trinav Infusion ,
Ambulatory Payment Classification ,
World Data Demonstrates Ability ,
Successfully Treat Patients ,
Higher Disease Burden ,
Improve Delivery ,
Pressure Enabled Drug Delivery ,
Multiple Phase ,
Uveal Melanoma Liver Metastases ,
Hepatocellular Cancer ,
Leading Academic Oncology Centers Across ,
Determine Which Indication ,
Full Data Set Will ,
Second Half ,
Cancer Center ,
Novel Pancreatic Infusion ,
Pancreatic Infusion System ,
Trinav Large ,
Financial Results ,
Full Year ,
Late Filing ,
Annual Report ,
Infusion System ,
Pancreatic Retrograde Venous Infusion System ,
Pressure Enabled Regional Immuno Oncology ,
Private Securities Litigation Reform Act ,
Balance Sheets ,
Stockholder Equity ,
vimarsana.com © 2020. All Rights Reserved.